Boston Scientific BSX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net sales of reportable segments by Business | ||||||
| Cardiovascular | $13.64B+2.6% | $13.29B+3.8% | $12.8B+4.8% | $12.22B+5.9% | $11.54B+6.4% | |
| MedSurg | $6.93B+1.3% | $6.84B+2.5% | $6.67B+3.6% | $6.44B+3.5% | $6.22B+3.2% | |
| Net Sales by Product | ||||||
| Cardiac Rhythm Management | $2.33B0.0% | $2.33B+0.9% | $2.31B+0.7% | $2.3B+0.6% | $2.28B+0.1% | |
| Electrophysiology | $3.5B+5.3% | $3.33B+7.8% | $3.08B+12.3% | $2.75B+17.7% | $2.33B+22.6% | |
| Endoscopy | $2.98B+2.2% | $2.92B+2.4% | $2.85B+2.5% | $2.78B+2.2% | $2.72B+1.2% | |
| Neuromodulation | $1.25B+3.9% | $1.2B+2.9% | $1.17B+2.2% | $1.14B+1.9% | $1.12B+1.4% | |
| Urology | $2.72B+0.5% | $2.71B+3.3% | $2.62B+6.1% | $2.47B+6.5% | $2.32B+5.5% | |
| Watchman | $2.04B+4.1% | $1.96B+6.6% | $1.84B+7.7% | $1.7B+6.7% | $1.6B+5.3% | |
| Net Sales by Geography | ||||||
| Asia-Pacific | $3.18B+3.3% | $3.08B+3.5% | $2.98B+4.1% | $2.86B+4.4% | $2.74B+2.0% | |
| Europe, Middle East and Africa | $3.54B+2.5% | $3.45B+3.1% | $3.35B+0.6% | $3.33B+1.7% | $3.27B+1.3% | |
| Latin America and Canada | $708M+4.4% | $678M+3.7% | $654M+2.5% | $638M+1.1% | $631M+1.0% | |
| U.S. | $13.19B+2.5% | $12.86B+4.0% | $12.37B+6.0% | $11.67B+6.9% | $10.91B+6.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Boston Scientific break its business down?
- Boston Scientific (BSX) reports net sales of reportable segments by business across 2 parts — Cardiovascular and MedSurg. Each is extracted from the segment footnotes and tracked over time.
- Where does Boston Scientific's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Boston Scientific's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
